Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

INDP Relative to the S&P 500

INDP Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Indaptus Therapeutics Inc (NASD:INDP) seasonal charts above shows that a Buy Date of July 27 and a Sell Date of October 18 has resulted in a geometric average return of 25.34% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 59.61% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. The company’s pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin’s lymphoma models.

To download INDP seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: INDP